• QSHXO Modulates Autophagy and Ferroptosis in MASLD Models

  2026-06-23

  Liu et al. reveal that Qushi Huoxue ointment (QSHXO) ameliorates metabolic associated steatotic liver disease (MASLD) in mice via coordinated activation of autophagy and inhibition of ferroptosis. These mechanistic insights provide a stronger basis for targeted MASLD interventions and inform future research on Nrf2 pathway modulation.

• nor-NOHA Acetate: Precision Arginase Inhibition in Immunomet

  2026-06-23

  Explore how nor-NOHA acetate enables precise, reversible arginase inhibition for dissecting immune escape and arginine metabolism in cancer research. This article reveals new mechanistic insights and practical guidance for translational applications.

• Circadian Glycogenomics: Timing, Quantification, and Transla

  2026-06-22

  Morning exercise timing drives distinct metabolic adaptations in mice, underscoring the critical importance of precise glycogen quantification in translational research. This thought-leadership article explores mechanistic insights, experimental validation, and strategic considerations for leveraging advanced glycogen assay kits, such as APExBIO’s Glycogen Colorimetric Assay Kit II, to accelerate discovery in metabolic and circadian biology.

• GDC-0941: Precision PI3K Inhibition for Overcoming Cancer Re

  2026-06-22

  Explore how GDC-0941, a potent PI3K inhibitor, uniquely enables researchers to dissect and overcome therapy resistance in cancer. This article delivers an in-depth, mechanism-driven perspective not found in standard product guides.

• Rotenone: Mitochondrial Complex I Inhibitor for Disease Mode

  2026-06-21

  Rotenone is a potent mitochondrial Complex I inhibitor widely used to induce mitochondrial dysfunction in cellular and animal models. It enables precise modeling of neurodegenerative disease pathways and autophagy. This article details Rotenone's mechanism, benchmarks, and best practices for reproducible research.

• Tropifexor (LJN452) Restores Intestinal Barrier in PN Piglet

  2026-06-20

  This study demonstrates that Tropifexor (LJN452), a potent FXR agonist, significantly mitigates parenteral nutrition-induced intestinal injury in neonatal piglets. The findings highlight the compound’s ability to restore barrier integrity and defense gene expression, offering new mechanistic insight and a potential research strategy for pediatric nutrition-related injury.

• Weight Loss Restores Gut Stretch-Induced Satiety in Obesity

  2026-06-19

  This study uncovers that intestinal stretch acutely suppresses food intake and enhances glucose tolerance, but obesity impairs this mechanosensory pathway. Both dietary and surgical weight loss restore the gut's ability to signal satiety via stretch, revealing a non-hormonal mechanism for metabolic regulation with implications for type II diabetes research.

• Disrupting SARS-CoV-2 Nucleocapsid Phase Separation: A Mecha

  2026-06-19

  The referenced study uncovers how the SARS-CoV-2 nucleocapsid (N) protein undergoes RNA-triggered liquid–liquid phase separation (LLPS), a process critical for viral replication and assembly. It further demonstrates that (-)-gallocatechin gallate (GCG) from green tea can disrupt this phase separation, offering a novel antiviral mechanism and a potential therapeutic strategy against COVID-19.

• THZ1: Covalent CDK7 Inhibitor Advancing T-ALL Research

  2026-06-18

  THZ1, a selective covalent CDK7 inhibitor from APExBIO, delivers unmatched precision for dissecting transcription regulation and cancer cell viability, especially in T-ALL models. This guide unpacks experimental workflows, protocol enhancements, and troubleshooting strategies to maximize the impact of THZ1-driven research.

• Dual Recombinase Tracing Refutes Postnatal Neo-oogenesis in

  2026-06-18

  A recent study rigorously applied dual recombinase-mediated genetic tracing to test whether new oocytes form after birth in mice. The findings show that neither physiological conditions nor busulfan-induced injury trigger neo-oogenesis, providing strong evidence for a fixed ovarian reserve and refining experimental models in reproductive biology.

• Trelagliptin Succinate: Selective DPP-4 Inhibition in Diabet

  2026-06-17

  Trelagliptin succinate (SYR-472 succinate) is a long-acting, selective DPP-4 inhibitor with once-weekly oral dosing, enabling robust glycemic control and mechanistic insights in type 2 diabetes research. This article details its molecular action, validated applications, and protocol parameters, with a focus on evidence-backed claims and common misconceptions.

• D-Luciferin: Firefly Luciferase Substrate for Tumor Imaging

  2026-06-17

  D-Luciferin enables ultra-sensitive, non-invasive bioluminescence imaging for real-time tumor burden assessment and intracellular ATP quantification. This guide details experimental setups, workflow optimizations, and troubleshooting strategies—distilling complex research findings into actionable protocols for both in vitro and in vivo applications.

• Synthetic Cleavage-Resistant TREM2 Enhances Macrophage Effer

  2026-06-16

  Dong et al. developed a synthetic, cleavage-resistant TREM2 receptor (CRT) that enhances macrophage efferocytosis even under inflammatory conditions. Using lipid nanoparticle-mediated mRNA delivery, CRT expression in macrophages restores apoptotic cell clearance and reduces inflammation in models of steatohepatitis and atherosclerosis.

• Oltipraz: Precision Nrf2 Activation for MASLD & Chemoprevent

  2026-06-16

  Oltipraz, a potent Nrf2 pathway activator, streamlines experimental workflows for chemoprevention and MASLD research by enabling reproducible phase II enzyme induction. This article demystifies protocol parameters, troubleshooting, and the translation of autophagy and ferroptosis modulation into tangible assay enhancements.

• Deferoxamine Mesylate: Iron-Chelating Agent in Advanced Work

  2026-06-15

  Deferoxamine mesylate stands as a versatile iron-chelating agent, enabling researchers to precisely modulate oxidative stress, hypoxia signaling, and tumor growth inhibition in breast cancer. This article delivers actionable workflow protocols, troubleshooting guidance, and translational insights for maximizing the impact of APExBIO’s Deferoxamine mesylate across oncology, regenerative medicine, and ferroptosis studies.

15699 records 1/1047 page Next 12345 下5页 Last page